- Home
- KC vs ACLX Comparison
KC vs ACLX Comparison
Compare KC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KC
- ACLX
- Stock Information
- Founded
- KC 2012
- ACLX 2015
- Country
- KC China
- ACLX United States
- Employees
- KC N/A
- ACLX N/A
- Industry
- KC Computer Software: Prepackaged Software
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- KC Technology
- ACLX Health Care
- Exchange
- KC Nasdaq
- ACLX Nasdaq
- Market Cap
- KC 3.7B
- ACLX 4.4B
- IPO Year
- KC 2020
- ACLX 2022
- Fundamental
- Price
- KC $12.56
- ACLX $91.72
- Analyst Decision
- KC Strong Buy
- ACLX Strong Buy
- Analyst Count
- KC 4
- ACLX 9
- Target Price
- KC $13.55
- ACLX $115.50
- AVG Volume (30 Days)
- KC 1.6M
- ACLX 544.4K
- Earning Date
- KC 11-19-2025
- ACLX 11-05-2025
- Dividend Yield
- KC N/A
- ACLX N/A
- EPS Growth
- KC N/A
- ACLX N/A
- EPS
- KC N/A
- ACLX N/A
- Revenue
- KC $1,177,715,737.00
- ACLX $35,898,000.00
- Revenue This Year
- KC $25.35
- ACLX N/A
- Revenue Next Year
- KC $16.46
- ACLX $220.95
- P/E Ratio
- KC N/A
- ACLX N/A
- Revenue Growth
- KC 20.27
- ACLX N/A
- 52 Week Low
- KC $5.44
- ACLX $47.86
- 52 Week High
- KC $22.26
- ACLX $96.39
- Technical
- Relative Strength Index (RSI)
- KC 51.57
- ACLX 60.30
- Support Level
- KC $11.48
- ACLX $87.85
- Resistance Level
- KC $12.75
- ACLX $92.91
- Average True Range (ATR)
- KC 0.67
- ACLX 3.65
- MACD
- KC 0.17
- ACLX 0.04
- Stochastic Oscillator
- KC 79.67
- ACLX 80.78
About KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.